New hope for tough blood cancers: experimental drug CC312 enters human testing
NCT ID NCT06037018
First seen Nov 01, 2025 · Last updated Apr 30, 2026 · Updated 24 times
Summary
This early-stage study tests a new drug called CC312 in about 44 adults with B-cell blood cancers (like some lymphomas and leukemias) that have returned or stopped responding to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it helps shrink tumors. Participants will receive the drug through an IV and be closely monitored for side effects and treatment response.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
InstituteHBDH
RECRUITINGTianjin, Tianjin Municipality, 300020, China
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.